Unnati Pharmax

Nindanib Nintedanib 150mg Capsules
Composition: Nintedanib 150mg Capsules
International Trade Name: Ofev®

Nindanib 150mg is a high-quality Nintedanib capsule formulation, a potent triple angiokinase inhibitor widely recognized under the international brand name Ofev®. Manufactured in WHO-GMP certified facilities, Nindanib is supplied by trusted pharmaceutical exporters from India to support advanced global treatment programs for fibrotic lung diseases and oncology indications.

Nintedanib works by inhibiting multiple tyrosine kinases, including VEGFR, FGFR, and PDGFR, thereby reducing fibroblast proliferation, angiogenesis, and disease progression. Nindanib 150mg Capsules are primarily indicated for the treatment of idiopathic pulmonary fibrosis (IPF) to slow disease progression and for select indications in oncology, including certain non-small cell lung cancers (NSCLC) in combination therapy.

Nindanib 150mg Capsules are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for pulmonology clinics, oncology centers, tertiary care hospitals, and international pharmaceutical distributors.

Nintib 100 Soft Gelatin Capsules
Composition: Nintedanib 100 mg per capsule
International Trade Name: Ofev®

Nintib 100 is a high-quality Nintedanib soft gelatin capsule, a biosimilar equivalent of the internationally recognized antifibrotic and tyrosine kinase inhibitor Ofev®. Manufactured in WHO-GMP certified facilities, Nintib is supplied by trusted pharmaceutical exporters from India to support advanced global pulmonary and oncology treatment programs.

Nintedanib is a triple angiokinase inhibitor that targets vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors. By inhibiting these pathways, Nintib slows disease progression in conditions characterized by abnormal tissue fibrosis and angiogenesis.

Nintib 100 mg Soft Gelatin Capsules are primarily indicated for the treatment of idiopathic pulmonary fibrosis (IPF), chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, and as an adjunct therapy in certain solid tumors, as prescribed by a healthcare professional.

Nintib 100 Soft Gelatin Capsules are manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, pulmonology and oncology clinics, government health programs, and international pharmaceutical distributors.

Nindalieva 150 mg Capsules
Composition: Nintedanib 150 mg per capsule
International Trade Name: Ofev®

Nindalieva 150 mg is a high-quality Nintedanib capsule, a biosimilar equivalent of the internationally recognized antifibrotic and tyrosine kinase inhibitor Ofev®. Manufactured in WHO-GMP certified facilities, Nindalieva is supplied by trusted pharmaceutical exporters from India to support advanced global pulmonary and oncology treatment programs.

Nintedanib is a triple angiokinase inhibitor that targets vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors. By inhibiting these pathways, Nindalieva slows disease progression in conditions characterized by abnormal tissue fibrosis and angiogenesis.

Nindalieva 150 mg Capsules are primarily indicated for the treatment of idiopathic pulmonary fibrosis (IPF), chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, and as an adjunct therapy in certain solid tumors, as prescribed by a healthcare professional.

Nindalieva 150 mg Capsules are manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, pulmonology and oncology clinics, government health programs, and international pharmaceutical distributors.

Nintib (Nintedanib) 150 mg, also marketed under the brand name Ofev, is a prescription medication primarily used in the management of idiopathic pulmonary fibrosis (IPF) and other serious, progressive lung diseases. It belongs to a class of drugs known as tyrosine kinase inhibitors, which work by blocking specific pathways involved in inflammation, fibrosis, and abnormal tissue remodeling in the lungs. By targeting these pathways, Nintib helps slow the progression of lung damage rather than curing the disease.

What is Nintedanib used for?

Nintedanib 150 mg is most commonly prescribed for:

• Idiopathic Pulmonary Fibrosis (IPF) – a chronic, progressive lung disease characterized by scarring (fibrosis) of lung tissue, leading to worsening shortness of breath and reduced oxygen exchange.

• Chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, including autoimmune-related ILDs.

• Systemic sclerosis–associated interstitial lung disease (SSc-ILD), where fibrosis affects lung function in patients with systemic sclerosis.

Clinical studies have shown that Nintedanib can significantly reduce the rate of decline in forced vital capacity (FVC), a key measure of lung function. While it does not reverse existing fibrosis, slowing disease progression can help preserve quality of life and functional capacity for a longer period.

How Nintib works

Nintedanib is a multi-targeted tyrosine kinase inhibitor. It blocks receptors involved in fibrotic processes, including:

• Vascular endothelial growth factor (VEGF) receptors

• Fibroblast growth factor (FGF) receptors

• Platelet-derived growth factor (PDGF) receptors

These receptors play a role in fibroblast activation and collagen deposition, which contribute to lung scarring. By inhibiting these signaling pathways, Nintib reduces ongoing fibrotic activity in lung tissue.

Dosage and administration

The standard recommended dose is 150 mg taken orally twice daily, approximately 12 hours apart, preferably with food to improve tolerability. Capsules should be swallowed whole with water and should not be crushed or chewed.

Dose adjustments or temporary interruptions may be necessary if side effects occur, especially gastrointestinal symptoms or liver enzyme elevations. In some cases, the dose may be reduced to 100 mg twice daily based on individual tolerance and physician guidance.

Laboratory abnormalities, particularly elevated liver enzymes, can occur, which is why regular liver function monitoring is required before and during treatment. Less commonly, patients may experience bleeding events, hypertension, or cardiovascular issues.

Patients with liver disease, bleeding disorders, or those taking anticoagulants should use Nintedanib with caution and under strict medical supervision.

Drug interactions and precautions

Nintedanib may interact with certain medications, including:

• Anticoagulants (blood thinners)

• Strong CYP enzyme inhibitors or inducers

• Certain antifungal or antibiotic medications

It is important for patients to inform their healthcare provider about all medications, supplements, and herbal products they are taking before starting therapy.

Nintib is not recommended during pregnancy, as it may harm an unborn baby. Effective contraception is advised for women of childbearing potential during treatment.

AFANAT 20mg Afatinib Dimaleate Tablets
Composition: Afatinib Dimaleate 20mg Tablets
International Trade Name: Gilotrif®

AFANAT 20mg is a high-quality Afatinib Dimaleate tablet formulation, a potent and irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor widely recognized under the international brand name Gilotrif®. Manufactured in WHO-GMP certified facilities, AFANAT is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in non-small cell lung cancer (NSCLC) with EGFR mutations.

Afatinib works by irreversibly binding to the tyrosine kinase domains of EGFR, HER2, and HER4, blocking downstream signaling pathways responsible for tumor cell proliferation, survival, and metastasis. AFANAT 20mg Tablets are primarily indicated for the treatment of patients with metastatic NSCLC harboring EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.

AFANAT 20mg Afatinib Dimaleate Tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Posid 100mg Etoposide Injection
Composition: Etoposide 100mg / Vial Injection
International Trade Name: Vepesid®

Posid 100mg is a high-quality Etoposide injectable formulation, a semisynthetic podophyllotoxin derivative widely recognized under the international brand name Vepesid®. Manufactured in WHO-GMP certified facilities, Posid Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Etoposide works by inhibiting topoisomerase II, an enzyme responsible for DNA unwinding during replication, leading to DNA strand breaks and apoptosis in rapidly dividing cancer cells. Posid 100mg Injection is primarily indicated for the treatment of small cell lung cancer, testicular cancer, lymphomas, and other solid tumors, either as monotherapy or in combination chemotherapy regimens.

Posid 100mg Etoposide Injection is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Alkros One Crizotinib Capsules 250mg
Composition: Crizotinib 250mg Capsules
International Trade Name: Xalkori®

Alkros One 250mg is a high-quality Crizotinib capsule formulation, a potent and selective tyrosine kinase inhibitor (TKI) widely recognized under the international brand name Xalkori®. Manufactured in WHO-GMP certified facilities, Alkros One is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in non-small cell lung cancer (NSCLC) with ALK or ROS1 gene rearrangements.

Crizotinib works by selectively inhibiting ALK (anaplastic lymphoma kinase) and ROS1 tyrosine kinases, blocking downstream signaling pathways involved in cancer cell proliferation and survival. Alkros One 250mg Capsules are primarily indicated for the treatment of patients with locally advanced or metastatic NSCLC harboring ALK or ROS1-positive genetic alterations.

Alkros One Crizotinib 250mg Capsules are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

 

Erlonat 150 Tablets
Composition: Erlotinib 150 mg per tablet
International Trade Name: Tarceva®

Erlonat 150 mg is a high-quality Erlotinib tablet, a biosimilar equivalent of the internationally recognized targeted therapy Tarceva®. Manufactured in WHO-GMP certified facilities, Erlonat is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly for patients with non-small cell lung cancer (NSCLC) and pancreatic cancer.

Erlotinib is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that blocks EGFR-mediated signaling pathways. By inhibiting EGFR activation, Erlonat suppresses tumor cell proliferation, induces apoptosis, and reduces metastasis, making it an effective therapy for EGFR mutation-positive cancers.

Erlonat 150 mg Tablets are primarily indicated for the treatment of metastatic or locally advanced NSCLC with EGFR-activating mutations and for pancreatic cancer in combination with gemcitabine, as prescribed by an oncologist.

Erlonat 150 mg Tablets are manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, hospitals, government cancer programs, and international pharmaceutical distributors.

 

AFANAT 30 mg Tablets
Composition: Afatinib Dimaleate 30 mg per tablet
International Trade Name: Gilotrif®

AFANAT 30 mg is a high-quality Afatinib Dimaleate tablet, a biosimilar equivalent of the internationally recognized targeted therapy Gilotrif®. Manufactured in WHO-GMP certified facilities, AFANAT is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations.

Afatinib is an irreversible tyrosine kinase inhibitor (TKI) that selectively blocks signaling from the epidermal growth factor receptor (EGFR) family, including EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4). By inhibiting these pathways, AFANAT helps prevent tumor cell proliferation, survival, and metastasis, making it an effective therapy for EGFR mutation-positive NSCLC.

AFANAT 30 mg Tablets are primarily indicated for the first-line treatment of patients with metastatic NSCLC whose tumors have non-resistant EGFR mutations, as prescribed by an oncologist.

AFANAT 30 mg Tablets are manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, hospitals, government cancer programs, and international pharmaceutical distributors.

Pemetero 500 Pemetrexed Injection
Composition: Pemetrexed 500 mg per vial
International Trade Name: Alimta®

Pemetero 500 is a high-quality Pemetrexed injection, a biosimilar equivalent of the internationally recognized chemotherapeutic agent Alimta®. Manufactured in WHO-GMP certified facilities, Pemetero is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Pemetrexed is an antifolate chemotherapeutic agent that inhibits multiple folate-dependent enzymes involved in the synthesis of DNA and RNA, thereby preventing cancer cell proliferation and inducing apoptosis. Pemetero is particularly effective in rapidly dividing tumor cells.

Pemetero 500 Injection is primarily indicated for the treatment of malignant pleural mesothelioma and non-small cell lung cancer (NSCLC), either as monotherapy or in combination regimens, as prescribed by an oncologist.

Pemetero 500 Pemetrexed Injection is manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, export-grade vials with complete regulatory documentation, making it suitable for oncology centers, hospitals, government cancer programs, and international pharmaceutical distributors.

PEMETYRA Pemetrexed Injection IP 500mg
Composition: Pemetrexed 500mg / Vial Injection
International Trade Name: Alimta®

PEMETYRA 500mg is a high-quality Pemetrexed injectable formulation, an antifolate chemotherapeutic agent widely recognized under the international brand name Alimta®. Manufactured in WHO-GMP certified facilities, PEMETYRA Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Pemetrexed works by inhibiting multiple folate-dependent enzymes involved in nucleotide synthesis, leading to disruption of DNA and RNA synthesis and inducing apoptosis in rapidly dividing cancer cells. PEMETYRA 500mg Injection is primarily indicated for the treatment of malignant pleural mesothelioma and non-small cell lung cancer (NSCLC), either as monotherapy or in combination with platinum-based chemotherapeutic agents.

PEMETYRA Pemetrexed Injection 500mg is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Pexate 500 Pemetrexed Injection
Composition: Pemetrexed 500mg / Vial Injection
International Trade Name: Alimta®

Pexate 500 is a high-quality Pemetrexed injectable formulation, an antifolate chemotherapeutic agent widely recognized under the international brand name Alimta®. Manufactured in WHO-GMP certified facilities, Pexate Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Pemetrexed works by inhibiting multiple folate-dependent enzymes involved in the synthesis of DNA and RNA, leading to disruption of cell proliferation and induction of apoptosis in rapidly dividing cancer cells. Pexate 500 Injection is primarily indicated for the treatment of malignant pleural mesothelioma and non-small cell lung cancer (NSCLC), either as monotherapy or in combination with platinum-based chemotherapy agents.

Pexate 500 Pemetrexed Injection is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.